Alzheimer’s blood testing is branching from diagnosis into prognosis
Europe — Spain and Central Europe, with research collaborators in the United States and Australia
Share ↗
The signal
A CE-marked mitochondrial-epigenetic blood test moving into international diagnostic distribution suggests Alzheimer’s blood testing may split into complementary markets: pathology detection and prognosis of cognitive decline.
The clue
Spain’s ADmit Therapeutics signed a distribution agreement with HVD Life Sciences for MAP-AD, a blood test intended to estimate whether mild cognitive impairment will progress to Alzheimer’s dementia.
Unlike increasingly familiar amyloid and tau blood tests, MAP-AD uses mitochondrial DNA methylation alongside genetic, clinical and cognitive inputs. Its underlying 2025 study reported results from an independent test set, while the product has received European IVDR certification.
Why it matters
Blood-based Alzheimer’s testing may be dividing into complementary functions:
- Detecting disease-associated pathology - Estimating the likelihood of clinical progression - Selecting or stratifying trial participants - Monitoring treatment response
If prognostic tests prove useful outside developer-led studies, laboratories and care providers may need multi-test workflows rather than one universal Alzheimer’s assay.
Evidence and interpretation
- Observed facts: A peer-reviewed study evaluated the mitochondrial-marker model, the test received European certification, and a diagnostic distributor is now taking it into additional markets. - Interpretation: Commercial infrastructure is beginning to form around prognosis as a distinct diagnostic use case. - Speculation: Prognostic biomarkers could become a separate procurement category, but evidence remains too early to assume routine clinical adoption.
What to watch next
The signal strengthens with prospective multicenter replication, adoption by independent laboratories, payer coverage, and evidence that prognosis changes care or trial enrollment; it weakens if performance fails to replicate outside the developer’s cohorts or if plasma amyloid/tau tests absorb the prognostic workflow.